Online inquiry

IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15423MR)

This product GTTS-WQ15423MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15423MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8859MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ14001MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ10548MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY­3074828
GTTS-WQ9428MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IPH-2201
GTTS-WQ15219MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ7221MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ9309MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMP-321
GTTS-WQ3859MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BCD-089
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW